Cargando…
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
Despite generally high cure rates in patients with metastatic germ cell cancer, patients with progressive disease on first-line cisplatin-based chemotherapy or with relapsed disease following high-dose salvage therapy exhibit a very poor prognosis. Irinotecan has shown antitumour activity in human t...
Autores principales: | Kollmannsberger, C, Rick, O, Klaproth, H, Kubin, T, Sayer, H G, Hentrich, M, Welslau, M, Mayer, F, Kuczyk, M, Spott, C, Kanz, L, Bokemeyer, C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364262/ https://www.ncbi.nlm.nih.gov/pubmed/12232755 http://dx.doi.org/10.1038/sj.bjc.66000524 |
Ejemplares similares
-
Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
por: Kollmannsberger, C, et al.
Publicado: (2003) -
Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
por: Bokemeyer, C., et al.
Publicado: (1998) -
Long-term effects on sexual function and fertility after treatment of testicular cancer
por: Hartmann, J T, et al.
Publicado: (1999) -
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET
por: Bokemeyer, C, et al.
Publicado: (2002) -
First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial
por: Bokemeyer, C, et al.
Publicado: (2003)